Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK0364
taranabant · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| taranabant | DRUG | - |
| MK0364 | DRUG | - |
Inclusion Criteria: * Obese patients with a body mass index between 30kg/m2 and 43 kg/m2, inclusive (BMI between 27 kg/m2 and 43kg/m2, inclusive for those with obesity-related comorbidities including hypertension, dyslipidemia and sleep apnea). Exclusion Criteria: * Patients with serious or unsta...
Taranabant is an investigational small-molecule drug developed by Merck & Company, Inc. (MRK) for obesity and obesity-related medical conditions, as well as smoking cessation. It was studied in Phase 2 clinical trials but is not approved for any indication.
Taranabant was being developed for the treatment of obesity and obesity-related medical conditions, and separately as an aid for smoking cessation in chronic cigarette smokers. It remains an investigational therapy and has not been approved for any use.
Taranabant targets CNR1, the cannabinoid receptor type 1, and acts as an inverse agonist. By binding to CNR1, it is designed to modulate receptor activity, which was explored for effects on appetite and body weight in obesity and for smoking cessation.
Taranabant was developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the Phase 2 clinical trials evaluating the drug in obesity and in smoking cessation.
Taranabant is in Phase 2 development. It has not been approved by the FDA or any regulatory agency. The clinical program includes completed Phase 2 trials, and no active trials are currently listed.
Taranabant has been studied in two completed Phase 2 trials: NCT00131430, an eighteen-month efficacy and safety study in obese patients with 500 participants, and NCT00109135, a study of taranabant as an aid for smoking cessation in chronic cigarette smokers with 300 participants.